Tergus is more than a team of people, it is a family. We believe in understanding each individual’s requirements and provide them with the opportunity to learn and grow. Employees are encouraged to engage in continuous learning and be ahead of the curve. Training is provided on a regular basis to facilitate professional growth. Our focus is to learn every day and produce quality work. In addition to maintaining strong technical acumen, Tergus peers guide each other every step of the way. We have key people in each business unit who work towards making Tergus a leader in topical product development.
Our Investors
Vijendra Nalamothu, Ph.D.
Executive Chairman & CSO, Tergus Pharma
Dr. Nalamothu holds a doctorate in Pharmaceutics from the University of the Sciences’ Philadelphia College of Pharmacy. His efforts over the past 26 years in various dermatological companies have led to many commercial products in the market today. He worked at Sanofi-Aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He also served as Global Head of Dermatology R&D at Promius Pharma, a wholly owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. He has successfully taken Tergus Pharma from a small R&D facility to a 100,000 square foot commercial manufacturing facility with industry-leading capabilities. His passion is to develop products that speak for themselves, leading him to take Tergus to its industry-leading position in the marketplace.
His knowledge of the unmet needs in the dermatology CDMO industry led to equipping Tergus Pharma with unique capabilities, such as Skin Biology and In Vitro Permeation (IVRT & IVPT), as well as Hormone and Highly Potent API compound (HPAPI) commercial manufacturing. Dr. Nalamothu draws from his unique background, which combines scientific study with pragmatic, hands-on experience, to solve R&D challenges and translate concepts into commercial products. Dr. Nalamothu’s interests include novel dosage form design and the development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles, and accolades. He is a sought-after speaker at conferences worldwide. He has co/authored numerous publications and holds multiple patents. He serves as a member of several pharmaceutical associations and sits on the boards of several pharmaceutical companies. In his spare time, Dr. Nalamothu enjoys quiet time with family and boating on Raleigh’s Falls Lake.
Eddie A. Hjerpe
Vice President, Great Point Partners
Mr. Hjerpe has been with Great Point Partners, a healthcare private equity fund, since 2015. He is currently a board member at Tergus Pharma and previously sat on the board of MaSTherCell Global. Mr. Hjerpe has actively worked on seven Great Point Partners investments, primarily focused on biopharma services and healthcare technology companies. Mr. Hjerpe graduated from the University of Notre Dame with a Master of Science in accountancy and a Bachelor of Business Administration in finance. Prior to Great Point, Mr. Hjerpe spent time at Sandler O’Neill & Partners, a boutique investment bank, and KPMG where he focused on financial due diligence consulting for private equity clients.
Scott Houlton
Great Point Partners CEO Advisory Board
Mr. Houlton became a member of the GPP CEO Advisory Board in 2018 after the sale of Clinical Supplies Management (CSM), a GPP II portfolio company. Mr. Houlton joined CSM as CEO in 2016, completed two European tuck-ins (Belgium and Germany) and tripled revenues Twenty-three months later, in September 2018, he led the sale of the business to Clinigen, resulting in a 4.9x multiple of invested capital and 125% IRR. Previously, Mr. Houlton was President at Catalent Pharma Solutions where, over a five-year period, he increased revenue from $140 million to $450 million and EBITDA from $24 million to $100 million. Prior to Catalent, he was the Chief Operating Officer at Aptuit. Mr. Houlton graduated cum laude with a Bachelor of Science degree in Finance and International Business from Ohio State University.
Prasad Inampudi
Founder, Kuber Capital Management LLC
Mr. Inampudi is the founder of Kuber Capital Management LLC, an investment management and strategy consulting firm, that advises and makes investments in small and mid-market private companies. Prior to founding Kuber, Mr. Inampudi was a General Partner of Omnicapital—a small, early-stage Venture Capital firm that invested in technology and medical device companies. Prior to Omnicapital, Mr. Inampudi was an investment manager of the Small and Mid-Cap Value Fund at AllianceBernstein. During his 10 year tenure at AllianceBernstein, Mr. Inampudi analyzed hundreds of companies across various sectors and made several investments. Prior to AllianceBernstein, Mr. Inampudi was the Director of Life Sciences at Oracle Corporation where he was responsible for product marketing and market strategy. Under his leadership, the company launched the industry’s first clinical trial management software. Early in his career, Mr. Inampudi worked as Director of Manufacturing at Regeneron Pharmaceuticals where he was responsible for the scale-up and manufacture of biologics. Mr. Inampudi has an M.B.A. degree from Harvard Business School and a B.S. degree from the Indian Institute of Technology at Bombay.
Dr. Devi Nalamothu, Pharm.D., R.Ph.
President, Tergus Pharma
Dr. Nalamothu has overseen the HR, Finance, and Operations departments since Tergus’ inception in 2012. In 2019, she delegated these day-to-day responsibilities to the newly hired Executive Leadership Team (ELT) and now plays a strategic role as a member of the Board of Directors. Dr. Nalamothu has over 26 years of Pharmaceutical experience, including and Medical Information Services with Merck, Sanofi, and PPD, after having been a Pharmacist in both national chain pharmacies and as an owner-operator. Dr. Nalamothu received her Doctor of Pharmacy at Shenandoah University in Virginia, and her Masters in Industrial Pharmacy from Long Island University, Brooklyn, NY.
Amit M. Patel
Executive Chairman, Azurity Pharmaceuticals
Mr. Patel has twenty years of healthcare industry experience with publicly traded, private equity-backed, and start-up companies, in the capacity of executive, board member, advisor, and investor. In addition to his current Executive Chairman role at Azurity Pharmaceuticals (a NovaQuest Capital Management portfolio company), he is also a board member at BioDuro (Advent International portfolio company), Tergus Pharma (Great Point Partners portfolio company) and Calyptus Pharma. Recently, Mr. Patel was SVP & President of Dosage Form Solutions at Capsugel, a KKR portfolio company (purchased from Pfizer in 2011 and sold to Lonza in 2017) that provided products and services to pharmaceutical and nutritional companies. Prior to Capsugel, he worked at Dr. Reddy’s Laboratories, Inc., a publicly traded, global specialty-generic pharmaceutical company where he held positions of EVP & Head, North America, and SVP & Head, Global Corporate Development & Strategic Planning. Earlier, Amit was VP, Corporate Development, at CTIS, Inc., and Co-founder & CEO of MedOnTime, Inc. (acquired by CTIS), both of which were healthcare information technology companies. He started his career as a consultant with Marakon Associates, a strategy consulting firm. Mr. Patel holds an M.B.A. degree from Harvard Business School, a B.S. degree in Economics from the Wharton School of Business, University of Pennsylvania, and a B.A.S. degree in Systems Engineering from the Moore School of Engineering, University of Pennsylvania.
Rohan Saikia
Managing Director, Great Point Partners
Mr. Saikia has over 13 years of health care private equity experience. He is currently a board member at American Surgical Professionals, Little Spurs Pediatric Urgent Care, MLM Medical Labs, and Tergus Pharma. He was previously a board member at Aris Radiology, Clinical Supplies Management and Professional Physical Therapy. Prior to joining Great Point Partners in 2007, Mr. Saikia was an investment banking analyst in Cowen and Company’s health care group, where he focused on mergers and acquisitions, private placements and public offerings of equity and convertible securities. Mr. Saikia earned a B.A. in Economics from Columbia University.